Our networking is well underway with investors and potential strategic partners for the JPM 2024. Attending the annual summit Lu Alleruzzo at JPM Healthcare Conference, Theresa Visarius at JPM Biotech Showcase, and Tomas Hode at RESI, in San Francisco January 8 -12, 2024.
Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a research collaboration with Johnson & Johnson Enterprise Innovation Inc. (JJEI) to explore the use of radiation in conjunction with Immunophotonics’ lead drug candidate, IP-001, as a novel immunotherapy approach for the treatment of solid tumor cancers. This collaboration agreement represents a...
Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President attending the AngioDynamics International Life Symposium taking place October 26 -28 in Monte Carlo, Monaco. They will be connecting with industry partners and clinical experts from around the world and discussing the latest breakthrough technologies.
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be attending ESMO Conference, October 20 – 24 in Madrid, Spain. They are excited to interact with key leaders, clinicians, researchers, and patient advocates from all over world to learn and brainstorm about the latest in oncology research and treatments.
Immunophotonics CEO Lu Alleruzzo will be participating at the ThinkEquity Conference in Mandarin Oriental, New York on October 19th. Check out his presentation at 12 pm in the Lotus Suite West and learn how Immunophotonics is treating the disease, not just the tumor – Abscopalize it!®
Immunophotonics Co-founder, CIO, and President Tomas Hode, PhD will be attending one of the most significant investor conferences in San Francisco, California, the Bio Investor Forum, October 17 – 18.
Immunophotonics CEO Lu Alleruzzo announced, along with Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as the Principal Investigator and National Coordinating Investigator at the University of Louisville, that the first patient has been dosed with IP-001 in the United States under Immunophotonics’ Investigational New Drug (IND) application with the FDA. The U.S....
Immunophotonics was recently granted approval by the NIH’s National Cancer Institute to transition from Phase I to Phase II Fast-track grant from Small Business Innovative Research (SBIR) for research regarding use of the company’s lead drug candidate, IP-001, in nonclinical models of Hepatocellular Carcinoma (HCC) in conjunction with thermal tumor ablation by microwave. This research...
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at Hôpital Foch in Suresnes. The protocol has been approved within the United States, United Kingdom, Switzerland, France, and Germany and will have over a dozen sites participating. The principal objective of this study is to...
Immunophotonics Co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Boston attending the RESI Boston 2023, September 18th, at Boston Park Plaza.
